November 1, 2017 Mustang Bio Announces MB-102 Data Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting
October 31, 2017 Mustang Bio Reports Preclinical Data on Regional Delivery of MB-103 HER2 Chimeric Antigen Receptor Engineered T (CAR T) Cells to Target HER2+ Breast Cancer Metastasis to the Brain
October 11, 2017 Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
September 14, 2017 Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies